Top Page
Incyte
(NASDAQ:INCY)
Incyte (INCY) vs. SPDR S&P 500 ETF (SPY)
Incyte Business Overview & Revenue Model
Incyte Key Performance Indicators (KPIs)
Analyzes revenue from different business units or product lines, highlighting which areas drive growth and profitability, and where strategic focus might be needed.
Main Street DataIncyte Earnings Call Summary
Incyte Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.81B | 4.24B | 3.70B | 3.39B | 2.99B | 2.67B |
| Gross Profit | 4.42B | 3.86B | 3.38B | 3.14B | 2.80B | 2.51B |
| EBITDA | 1.63B | 408.16M | 919.43M | 599.64M | 630.20M | -178.24M |
| Net Income | 1.19B | 32.62M | 597.60M | 340.66M | 948.58M | -295.70M |
Balance Sheet | ||||||
| Total Assets | 6.33B | 5.44B | 6.78B | 5.84B | 4.93B | 3.56B |
| Cash, Cash Equivalents and Short-Term Investments | 2.93B | 2.16B | 3.66B | 3.24B | 2.35B | 1.80B |
| Total Debt | 41.27M | 60.34M | 38.29M | 41.46M | 44.82M | 47.53M |
| Total Liabilities | 1.68B | 2.00B | 1.59B | 1.47B | 1.16B | 949.65M |
| Stockholders Equity | 4.65B | 3.45B | 5.19B | 4.37B | 3.77B | 2.61B |
Cash Flow | ||||||
| Free Cash Flow | 1.20B | 249.07M | 449.00M | 892.11M | 568.48M | -311.98M |
| Operating Cash Flow | 1.25B | 335.34M | 496.49M | 969.94M | 749.49M | -124.60M |
| Investing Cash Flow | -86.66M | 157.52M | -207.68M | -78.54M | -207.70M | -269.00M |
| Financing Cash Flow | -16.31M | -2.02B | -20.03M | -794.00K | 6.18M | 71.71M |
Incyte Technical Analysis
Incyte Risk Analysis
Incyte Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $19.94B | 17.04 | 30.39% | ― | 18.09% | 3563.21% | |
| ― | $19.18B | 16.88 | 20.04% | ― | 13.50% | 17.16% | |
| ― | $10.25B | 18.25 | 29.00% | ― | 10.73% | 81.66% | |
| ― | $17.47B | 14.17 | 26.08% | ― | 23.25% | 64.46% | |
| ― | $10.15B | 19.80 | 9.07% | ― | 12.31% | 60.21% | |
| ― | $12.17B | -40.45 | ― | ― | 55.77% | 46.81% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Incyte Corporate Events
Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, particularly in the fields of oncology and inflammation & autoimmunity. Headquartered in Wilmington, Delaware, Incyte operates across North America, Europe, and Asia.
Incyte’s recent earnings call painted a picture of robust financial health and strategic growth, with a positive sentiment underscored by impressive revenue figures and successful product launches. While the company faced some challenges with program terminations, the overall tone was optimistic, driven by strong performances from key products like Jakafi and Opzelura, and a successful launch of Niktimvo.
Incyte Corporation is conducting a Phase 3 clinical study titled ‘A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa.’ The study aims to evaluate the efficacy and safety of ruxolitinib cream for treating hidradenitis suppurativa, a chronic skin condition. This research is significant as it could offer a new topical treatment option for patients.
Study Overview: Incyte Corporation is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo. The study aims to evaluate the safety and efficacy of ruxolitinib cream in treating pediatric patients with nonsegmental vitiligo, a condition characterized by loss of skin pigmentation. This study is significant as it addresses a pediatric population, offering potential advancements in treatment options for this demographic.
Incyte Corporation is currently conducting a clinical study titled ‘An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants.’ The primary objective is to evaluate the pharmacokinetics and metabolite profiles of INCB123667, a drug administered to healthy male participants, to understand its absorption, distribution, metabolism, and excretion. This study is significant as it provides foundational data for the drug’s development.
Incyte Corporation is conducting a pivotal clinical trial titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis.’ This study aims to assess the efficacy and safety of povorcitinib, focusing on its impact on itch and skin lesions in individuals suffering from prurigo nodularis, a chronic skin condition.
Study Overview: Incyte Corporation is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357). The study aims to evaluate the effectiveness of axatilimab combined with corticosteroids compared to a placebo for treating moderate to severe chronic graft-versus-host disease (cGVHD), a condition that can occur after a stem cell or bone marrow transplant.
Incyte Corporation is conducting a clinical study titled ‘A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease After Systemic Therapy.’ The study aims to assess the safety and effectiveness of axatilimab in treating chronic graft-versus-host disease (cGVHD) in patients who have not responded to previous systemic therapies.
Incyte Corporation is currently recruiting participants for a Phase 3b study titled A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis. The study aims to evaluate the efficacy and safety of ruxolitinib cream in treating moderate atopic dermatitis in children and adolescents, highlighting its potential significance in pediatric dermatology.
Incyte Corporation is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa.’ The study aims to evaluate the efficacy and safety of ruxolitinib cream for treating hidradenitis suppurativa, a chronic skin condition.
Incyte Corporation is conducting a Phase 1, open-label, multicenter study titled ‘A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms.’ The primary objective is to assess the safety and tolerability of the drug INCA035784 in individuals with myeloproliferative neoplasms, a group of blood cancers. This study is significant as it aims to identify a new treatment option for these conditions.
Incyte Corporation is conducting a Phase 2 study titled A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. The study aims to assess the safety and efficacy of the drug INCB123667 in treating patients with platinum-resistant ovarian cancer exhibiting Cyclin E1 overexpression, a condition that limits treatment options and affects prognosis.
Incyte Corporation is currently conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (NCT06516965). The study aims to assess the efficacy and safety of povorcitinib, a drug intended to alleviate itch and skin lesions in individuals suffering from prurigo nodularis, a chronic skin condition.
Study Overview: Incyte Corporation is conducting a Phase 3b, multicenter rollover study titled A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib. The study aims to continue evaluating the safety and efficacy of povorcitinib, a drug for patients with Hidradenitis Suppurativa (HS), who were previously enrolled in related clinical trials. This study is significant as it seeks to provide further insights into long-term treatment outcomes for HS, a chronic skin condition.
Incyte Corporation is conducting a Phase 2, open-label study titled ‘A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa.’ The study aims to assess the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants suffering from moderate to severe hidradenitis suppurativa over a 54-week period. This research is significant as it targets a challenging skin condition with limited treatment options.
Incyte Corporation has announced a new Phase 3 study titled ‘A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator’s Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression.’ The study aims to evaluate the efficacy of INCB123667 compared to standard chemotherapy options in patients with a specific type of ovarian cancer, highlighting its potential significance in offering new treatment avenues for this challenging condition.
Incyte Corporation is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva. The study aims to assess the efficacy, safety, and tolerability of the drug INCB000928 in treating fibrodysplasia ossificans progressiva (FOP), a rare and debilitating condition.
Study Overview: Incyte Corporation is initiating a Phase 1 clinical trial titled ‘A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies.’ The study aims to assess the safety and tolerability of the experimental drug INCA036873 in patients with advanced solid tumors and hematological malignancies, marking a significant step in cancer treatment research.
Incyte Corporation is conducting a Phase 3 study titled ‘A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa.’ The study aims to assess the long-term safety and efficacy of povorcitinib, an oral tablet, in individuals with moderate to severe hidradenitis suppurativa who have completed 54 weeks of treatment in previous studies.
Incyte Corporation is conducting a clinical study titled ‘A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa.’ The study aims to evaluate the maximal use of ruxolitinib cream, a topical treatment, in managing hidradenitis suppurativa, a chronic skin condition. This research is significant as it explores a potential new treatment option for patients suffering from this painful condition.
Incyte Corporation is currently conducting a Phase III clinical trial titled ‘A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation.’ The study aims to evaluate the efficacy of two treatment regimens in preventing Graft-versus-host Disease (GVHD) in patients undergoing stem cell transplantation. This research is significant as it could lead to improved outcomes for patients with GVHD, a common complication after transplantation.
Incyte Corporation is currently conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo. The study aims to evaluate the efficacy and safety of ruxolitinib cream in treating nonsegmental vitiligo in children, a condition characterized by loss of skin pigmentation. This research is significant as it addresses a pediatric population with limited treatment options.
Incyte Corporation is conducting a Phase 1 study titled A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation. The study aims to assess the safety and tolerability of INCB161734, alone or in combination with other cancer therapies, in treating solid tumors with a specific genetic mutation. This research is significant as it targets the KRAS G12D mutation, a challenging target in cancer treatment.
Incyte Corporation is currently conducting a Phase 2 clinical study titled A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study aims to evaluate the effectiveness of different doses of povorcitinib on improving pulmonary function in individuals with moderate to severe asthma who do not respond adequately to existing treatments.
Incyte Corporation is conducting a Phase 2 study titled ‘A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease.’ The study aims to assess the preliminary efficacy of axatilimab when combined with ruxolitinib, focusing on its contribution to treatment effects in chronic graft-versus-host disease (cGVHD) patients.
Incyte Corporation is conducting a Phase 1 study titled A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms to evaluate the safety and tolerability of the drug INCB160058. The study aims to assess the pharmacokinetics of this treatment in individuals with myeloproliferative neoplasms, a group of blood cancers, which could lead to new therapeutic options for these conditions.
Incyte Corporation is conducting a study titled ‘A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE).’ The study aims to gather data from individuals who have undergone an allogeneic Stem Cell Transplant and are at risk of developing Chronic Graft-Versus-Host Disease (cGVHD). This research is significant as it seeks to improve understanding and management of cGVHD, a common complication post-transplant.
Incyte Corporation is currently conducting a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors. The study aims to evaluate the safety, tolerability, and dose-limiting toxicities of INCA33890, while determining the maximum tolerated dose and/or recommended dose for expansion in patients with advanced or metastatic solid tumors.
Incyte Corporation is conducting a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and preliminary efficacy of INCB123667, both as a standalone treatment and in combination with other anticancer therapies, for patients with advanced solid tumors.
Incyte Corporation is launching a new clinical study titled ‘A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256).’ The study aims to evaluate the effectiveness of Axatilimab compared to the best available therapy in children suffering from chronic graft-versus-host disease, a condition that occurs after a stem cell or bone marrow transplant. This study is significant as it targets patients who have already undergone at least two prior systemic therapies, highlighting the need for more effective treatment options.
Incyte Corporation is conducting a Phase 1 clinical study titled A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants. The primary goal is to evaluate the safety and tolerability of the drug INCB000631 in healthy adults, which is crucial for its potential future applications in treating various conditions.
Incyte Corporation is launching a Phase 2a, open-label, multicenter study to assess the safety and efficacy of tafasitamab in adults with primary autoimmune blood cell disorders. The study, officially titled ‘A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders,’ aims to evaluate the treatment’s potential in conditions like immune thrombocytopenia. This research is significant as it could offer new therapeutic options for patients with these challenging disorders.
Incyte Corporation is conducting an open-label study titled ‘An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants.’ The study aims to evaluate how different drugs, including itraconazole, rifampin, and acid-reducing agents, affect the pharmacokinetics of INCB161734, a new oral medication, in healthy individuals. This research is significant as it could influence the future use and development of INCB161734.
Incyte Corporation is currently recruiting for a clinical study titled A Phase 0, Evaluation of Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Patients. The study aims to assess the effectiveness of a microneedle device in collecting dermal interstitial skin fluid (dISF) from both healthy individuals and those with atopic dermatitis. This research is significant as it explores a non-invasive method that could potentially enhance patient comfort and compliance in dermatological assessments.
Incyte Corporation is conducting a significant study titled A US-Prospective, Registry-Based, Observational, Exposure Cohort Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population. The study aims to assess the frequency of major congenital malformations among infants born to women who used ruxolitinib cream during pregnancy compared to those who did not. This research is crucial in understanding the safety of ruxolitinib cream for pregnant women with atopic dermatitis.
Incyte Corporation is conducting an observational retrospective cohort study titled ‘Pregnancy Outcomes Study of Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis.’ The study aims to assess infant outcomes in women with atopic dermatitis (AD) who used ruxolitinib cream during pregnancy compared to those who used topical corticosteroids (TCS). This research is significant as it seeks to provide insights into the safety and effects of these treatments during pregnancy.
Incyte Corporation is conducting an extension study titled An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab. The study aims to continue providing tafasitamab treatment to patients with hematologic malignancies who have shown clinical benefits in previous studies. This research is significant as it seeks to further understand the long-term efficacy and safety of tafasitamab in treating these conditions.
Incyte Corporation is conducting a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms. The study aims to evaluate the safety, tolerability, and dose-limiting toxicity of INCA033989, both as a standalone treatment and in combination with Ruxolitinib, to determine the maximum tolerated dose for patients with myeloproliferative neoplasms.
Study Overview: Incyte Corporation is conducting a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms. The study aims to assess the safety, tolerability, and optimal dosing of INCA033989, alone or with Ruxolitinib, for treating myeloproliferative neoplasms, a group of blood cancers.
Study Overview: The clinical study titled Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide aims to evaluate the safety and efficacy of a combination treatment for patients with multiple myeloma. The study uses changes in serum B-Cell Maturation Antigen (BCMA) to determine disease progression, which is significant for tailoring treatment strategies for relapsed or refractory multiple myeloma.
Incyte Corporation is currently conducting a study titled realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients. The study aims to gather data on the safety and effectiveness of the drug combination in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with a particular focus on racial and ethnic minority patients.
On September 30, 2025, Incyte Corporation announced the appointment of Thomas Tray as the principal financial officer, effective September 16, 2025. Mr. Tray, who has been with the company since 2005, has held various roles, most recently as Vice President, Finance and Chief Accounting Officer. This appointment reflects the company’s confidence in Mr. Tray’s capabilities and could strengthen its financial leadership.
The most recent analyst rating on (INCY) stock is a Buy with a $89.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.
On August 4, 2025, Incyte Corporation announced that Christiana Stamoulis, the Executive Vice President and Chief Financial Officer, will step down from her role on September 16, 2025, to pursue another opportunity. The company is in the process of appointing a successor and Ms. Stamoulis will remain with the company until her departure to ensure a smooth transition.
The most recent analyst rating on (INCY) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.